Latest Theralase Technologi (TLTFF) Headlines
Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Bra...
ACCESSWIRE - Thu Feb 13, 6:01AM CST
Toronto, Ontario - February 13, 2014 - Theralase Technologies Inc. (TSXV: TLT) reported today that a recently published scientific paper demonstrated that its new family of Photo Dynamic Compounds (PDCs) has been proven to significantly destroy 2 types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments. Since the Theralase PDC platform technology is able to be used in both bacteria and cancer destruction, the described technology is offering a new paradigm for destruction of low oxygenated cancerous tumours. (Photodiagnosis Photodyn Ther. Dec;10(4):615-25).
Theralase Technologies: Novel Laser Technology for Blockbuster Bladder Cancer Market
ACCESSWIRE - Wed Feb 12, 9:20AM CST
2013 was a great year for Life Sciences stocks and the momentum created last year is being carried into 2014 - with a flurry of successful IPOs and financings. According to organizers at the JP Morgan Health Care Conference in January attendance was much higher than what they had anticipated and bankers were eager to do deals as more dollars flow into the space. As the wider market draws its attention to the sector the hunt for underexposed and undervalued companies is fast on. One such company is Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF); Theralase designs, develops, manufactures and markets, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. With a strong pipeline of developments leading to a Phase I clinical trial in 2015 the company looks to have a promising 2014.
Theralase Releases 3Q2013 Financial Results
ACCESSWIRE - Fri Nov 29, 6:02AM CST
Toronto, Ontario - November, 29, 2013 Theralase Technologies Inc. (TSXV: TLT) released its third quarter 2013 financial results today, demonstrating an increase in profitability by 40% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies.
Theralase Completes Oversubscribed $3.15 M Equity Financing
ACCESSWIRE - Thu Nov 07, 6:26AM CST
Toronto, Ontario -//Accesswire// November 7, 2013 Theralase Technologies Inc. (TSX-V: TLT) announced today that it has completed an oversubscribed equity financing raising CAN $3,150,000 via private placement offering. ("Private Placement")
Theralase Commences $3.15 M Equity Financing
ACCESSWIRE - Fri Nov 01, 6:08AM CDT
Toronto, Ontario - (Accesswire - November 1, 2013) Theralase Technologies Inc. (TSX-V: TLT) announced today that it has commenced an equity financing to raise up to CAN $3,150,000 via private placement ("Private Placement").
Theralase Updates Cancer Therapy Breakthrough
ACCESSWIRE - Wed Oct 09, 6:06AM CDT
Toronto, ON, (Accesswire - October 9, 2013) - On March 28, 2012, Theralase Technologies Inc. (TSXV: TLT) first announced that its anti-cancer technology was found to completely destroy highly aggressive, subcutaneous (under the skin) colon cancer tumours in a mouse model. At that point in time, 4 weeks post treatment, the mice continued to be cancer free.
Theralase Releases Financial Results for Second Quarter 2013
ACCESSWIRE - Fri Aug 30, 6:00AM CDT
Toronto, Ontario - August, 30, 2013 Theralase Technologies Inc. (TSXV: TLT) released its second quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies.
IIROC Trade Resumption - Theralase Technologies Inc.
Newsfile Corp - Thu Aug 29, 7:18AM CDT
Trading resumes in:
IIROC Trade Halt - Theralase Technologies Inc.
Newsfile Corp - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC:
IIROC: Halt, Theralase Technologies Inc.
Marketwire Canada - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants:
Theralase Releases Financial Results for First Quarter 2013
ACCESSWIRE - Thu May 30, 3:10PM CDT
Toronto, Ontario - May 30, 2013, Theralase Technologies Inc. (TSXV: TLT) released its first quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies .
Theralase Launches New Head Office and Therapeutic Laser Centre
ACCESSWIRE - Tue May 28, 6:00AM CDT
TH
Theralase Advanced Cancer Therapy Research Recognized at Major International Conference
ACCESSWIRE-TNW - Thu May 16, 6:00AM CDT
Toronto, Ontario - May 16, 2013, Theralase Technologies Inc. (TSXV: TLT) ("Theralase") announced today that its researchers have discovered a significant new mechanism of action for a new class of Photo Dynamic Compounds (PDCs), that have been custom designed to destroy cancer cells when activated by a proprietary light source.
Theralase Announces 2012 Year End Financials; Theralase Advances Therapeutic Laser and Cancer Destruction Technologies
ACCESSWIRE-TNW - Wed May 01, 3:00PM CDT
Toronto, Ontario - May 1, 2013, Theralase Technologies Inc. (TSXV: TLT) announced its year end 2012 financial results today.
Theralase Applies to TSX Venture Exchange for Warrant Extension
ACCESSWIRE-TNW - Thu Mar 28, 3:10PM CDT
Toronto, ON - March 28, 2013 - Theralase Technologies Inc. (TSXV: TLT) ("Theralase") announced today that it has made application to the TSX Venture Exchange for approval to extend the expiry date of its outstanding common share purchase warrants.
Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy
ACCESSWIRE-TNW - Thu Mar 14, 6:00AM CDT
Toronto, ON -- March 14, 2013 -- Theralase Technologies Inc. (TSXV: TLT) announced that its proprietary Photo Dynamic Compound (PDC) technology has been approved for use in a live animal bladder cancer model by the University Health Network (UHN) Research Ethics Board. This approval expedites the Company's progress towards commercializing its advanced bladder cancer therapy.
Theralase Expands Board of Directors with Strong Financing Capabilities
ACCESSWIRE-TNW - Fri Feb 01, 6:00AM CST
Toronto, Ontario - February 1, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced that effective today Mr. Matthew Perraton PFP, FMA, FCSI and Mr. Guy J. Anderson BA, CFP, CIM, FMA, FCSI, MBA have agreed to serve on the company's Board of Directors.
Renowned Oncologist Dr. Michael Jewett Joins Theralase's Medical and Scientific Advisory Board
ACCESSWIRE-TNW - Tue Jan 29, 7:00AM CST
Toronto, Ontario -January 29, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) is pleased to announce that effective January 15, 2013, Michael Jewett MD, FRCSC, FACS has elected to join its Medical and Scientific Advisory Board.
Theralase Demonstrates Bacteria Destruction in Low Oxygen Environments. Unique Characteristics of New Photo Dynamic Compounds has Application in Destruction of Lung, Breast, Bra...
ACCESSWIRE - Thu Feb 13, 6:01AM CST
Toronto, Ontario - February 13, 2014 - Theralase Technologies Inc. (TSXV: TLT) reported today that a recently published scientific paper demonstrated that its new family of Photo Dynamic Compounds (PDCs) has been proven to significantly destroy 2 types of bacteria (Staphylococcus aureus (s. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA)) in low oxygen atmospheres. The results are considered pivotal because the Theralase PDCs efficacy has been validated in both normal and low oxygen environments. Since the Theralase PDC platform technology is able to be used in both bacteria and cancer destruction, the described technology is offering a new paradigm for destruction of low oxygenated cancerous tumours. (Photodiagnosis Photodyn Ther. Dec;10(4):615-25).
Theralase Technologies: Novel Laser Technology for Blockbuster Bladder Cancer Market
ACCESSWIRE - Wed Feb 12, 9:20AM CST
2013 was a great year for Life Sciences stocks and the momentum created last year is being carried into 2014 - with a flurry of successful IPOs and financings. According to organizers at the JP Morgan Health Care Conference in January attendance was much higher than what they had anticipated and bankers were eager to do deals as more dollars flow into the space. As the wider market draws its attention to the sector the hunt for underexposed and undervalued companies is fast on. One such company is Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF); Theralase designs, develops, manufactures and markets, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. With a strong pipeline of developments leading to a Phase I clinical trial in 2015 the company looks to have a promising 2014.
Theralase Releases 3Q2013 Financial Results
ACCESSWIRE - Fri Nov 29, 6:02AM CST
Toronto, Ontario - November, 29, 2013 Theralase Technologies Inc. (TSXV: TLT) released its third quarter 2013 financial results today, demonstrating an increase in profitability by 40% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies.
Theralase Completes Oversubscribed $3.15 M Equity Financing
ACCESSWIRE - Thu Nov 07, 6:26AM CST
Toronto, Ontario -//Accesswire// November 7, 2013 Theralase Technologies Inc. (TSX-V: TLT) announced today that it has completed an oversubscribed equity financing raising CAN $3,150,000 via private placement offering. ("Private Placement")
Theralase Commences $3.15 M Equity Financing
ACCESSWIRE - Fri Nov 01, 6:08AM CDT
Toronto, Ontario - (Accesswire - November 1, 2013) Theralase Technologies Inc. (TSX-V: TLT) announced today that it has commenced an equity financing to raise up to CAN $3,150,000 via private placement ("Private Placement").
Theralase Updates Cancer Therapy Breakthrough
ACCESSWIRE - Wed Oct 09, 6:06AM CDT
Toronto, ON, (Accesswire - October 9, 2013) - On March 28, 2012, Theralase Technologies Inc. (TSXV: TLT) first announced that its anti-cancer technology was found to completely destroy highly aggressive, subcutaneous (under the skin) colon cancer tumours in a mouse model. At that point in time, 4 weeks post treatment, the mice continued to be cancer free.
Theralase Releases Financial Results for Second Quarter 2013
ACCESSWIRE - Fri Aug 30, 6:00AM CDT
Toronto, Ontario - August, 30, 2013 Theralase Technologies Inc. (TSXV: TLT) released its second quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies.
IIROC Trade Resumption - Theralase Technologies Inc.
Newsfile Corp - Thu Aug 29, 7:18AM CDT
Trading resumes in:
IIROC Trade Halt - Theralase Technologies Inc.
Newsfile Corp - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC:
IIROC: Halt, Theralase Technologies Inc.
Marketwire Canada - Tue Aug 27, 3:09PM CDT
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants:
Theralase Releases Financial Results for First Quarter 2013
ACCESSWIRE - Thu May 30, 3:10PM CDT
Toronto, Ontario - May 30, 2013, Theralase Technologies Inc. (TSXV: TLT) released its first quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies .
Theralase Launches New Head Office and Therapeutic Laser Centre
ACCESSWIRE - Tue May 28, 6:00AM CDT
TH
Theralase Advanced Cancer Therapy Research Recognized at Major International Conference
ACCESSWIRE-TNW - Thu May 16, 6:00AM CDT
Toronto, Ontario - May 16, 2013, Theralase Technologies Inc. (TSXV: TLT) ("Theralase") announced today that its researchers have discovered a significant new mechanism of action for a new class of Photo Dynamic Compounds (PDCs), that have been custom designed to destroy cancer cells when activated by a proprietary light source.
Theralase Announces 2012 Year End Financials; Theralase Advances Therapeutic Laser and Cancer Destruction Technologies
ACCESSWIRE-TNW - Wed May 01, 3:00PM CDT
Toronto, Ontario - May 1, 2013, Theralase Technologies Inc. (TSXV: TLT) announced its year end 2012 financial results today.
Theralase Applies to TSX Venture Exchange for Warrant Extension
ACCESSWIRE-TNW - Thu Mar 28, 3:10PM CDT
Toronto, ON - March 28, 2013 - Theralase Technologies Inc. (TSXV: TLT) ("Theralase") announced today that it has made application to the TSX Venture Exchange for approval to extend the expiry date of its outstanding common share purchase warrants.
Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy
ACCESSWIRE-TNW - Thu Mar 14, 6:00AM CDT
Toronto, ON -- March 14, 2013 -- Theralase Technologies Inc. (TSXV: TLT) announced that its proprietary Photo Dynamic Compound (PDC) technology has been approved for use in a live animal bladder cancer model by the University Health Network (UHN) Research Ethics Board. This approval expedites the Company's progress towards commercializing its advanced bladder cancer therapy.
Theralase Expands Board of Directors with Strong Financing Capabilities
ACCESSWIRE-TNW - Fri Feb 01, 6:00AM CST
Toronto, Ontario - February 1, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced that effective today Mr. Matthew Perraton PFP, FMA, FCSI and Mr. Guy J. Anderson BA, CFP, CIM, FMA, FCSI, MBA have agreed to serve on the company's Board of Directors.
Renowned Oncologist Dr. Michael Jewett Joins Theralase's Medical and Scientific Advisory Board
ACCESSWIRE-TNW - Tue Jan 29, 7:00AM CST
Toronto, Ontario -January 29, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) is pleased to announce that effective January 15, 2013, Michael Jewett MD, FRCSC, FACS has elected to join its Medical and Scientific Advisory Board.
